^
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
Sci Rep - 4 days
HER-2 mutation
Estrogen Receptor Positive Breast Cancer
trastuzumab + neratinib
Sensitive: C3 – Early Trials
Clin Cancer Res - 5 days
HER-2 mutation
Estrogen Receptor Positive Breast Cancer
neratinib
Sensitive: C3 – Early Trials
Clin Cancer Res - 5 days
HR positive
HER2 Negative Breast Cancer
PF-05212384
Sensitive: B - Late Trials
BioSpace - 6 days
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
Cancer Res Treat - 1 week
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
Daiichi Sankyo Press Release - 1 week
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib + GZ17-6.02
Sensitive: D – Preclinical
Oncotarget - 1 week
TP53 wild-type
Breast Cancer
selinexor + chidamide
Sensitive: D – Preclinical
Mol Cell Endocrinol - 1 week
TP53 wild-type
Breast Cancer
selinexor
Sensitive: D – Preclinical
Mol Cell Endocrinol - 1 week
TP53 wild-type
Breast Cancer
chidamide
Sensitive: D – Preclinical
Mol Cell Endocrinol - 1 week
HER-2 positive
HER2 Positive Breast Cancer
TCHP
Sensitive: A2 - Guideline
Cancer Res Treat - 2 weeks
AR positive + ER positive
HER2 Negative Breast Cancer
enobosarm
Sensitive: B - Late Trials
Veru Press Release - 2 weeks
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
- 2 weeks
HR positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A2 - Guideline
BMC Cancer - 2 weeks
SOX2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
Pharmacol Rep - 2 weeks
HER-2 negative
HER2 Negative Breast Cancer
eribulin mesylate
Sensitive: A2 - Guideline
BMC Cancer - 3 weeks
HER-2 positive
HER2 Positive Breast Cancer
pyrotinib
Sensitive: B - Late Trials
Anticancer Drugs - 3 weeks
ER positive
HER2 Negative Breast Cancer
CB-228
Sensitive: C2 – Inclusion Criteria
Clin Cancer Res - 3 weeks
LDH-H
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Resistant: C3 – Early Trials
BMC Cancer - 3 weeks
PTEN Hypermethylation
Hormone Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks
PTEN underexpression
Hormone Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks
CDYL2 overexpression
HER2 Positive Breast Cancer
trastuzumab
Resistant: C3 – Early Trials
Mol Cancer - 3 weeks
CDH1 deletion
Breast Cancer
vorinostat
Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
CDH1 deletion
Breast Cancer
MGCD0103
Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
CDH1 deletion
Breast Cancer
SB939
Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
CDH1 deletion
Breast Cancer
SNDX-275
Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks
CDYL2 overexpression
HER2 Positive Breast Cancer
FAK inhibitor
Sensitive: D – Preclinical
Mol Cancer - 3 weeks
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
No biomarker
Breast Cancer
TAC
Sensitive: A1 - Approval
HR positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A1 - Approval
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Breast Cancer
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
ribociclib
Sensitive: A1 - Approval
ER negative
Breast Cancer
toremifene
Resistant: A1 - Approval
No biomarker
Breast Cancer
toremifene
Sensitive: A1 - Approval
No biomarker
Breast Cancer
albumin-bound paclitaxel
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
lapatinib
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Negative Breast Cancer
trastuzumab + lapatinib
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
lapatinib
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
everolimus
Sensitive: A1 - Approval
BRCA2 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
BRCA1 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
trastuzumab
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + capecitabine
Sensitive: A1 - Approval
No biomarker
Breast Cancer
capecitabine
Sensitive: A1 - Approval
HR positive
HER2 Positive Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
No biomarker
Breast Cancer
eribulin mesylate
Sensitive: A1 - Approval
No biomarker
Breast Cancer
non-pegylated liposomal doxorubicin
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
trastuzumab/hyaluronidase-oysk
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
olaparib
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
No biomarker
Breast Cancer
bevacizumab
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Triple Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
exemestane
Sensitive: A1 - Approval
No biomarker
Breast Cancer
exemestane
Sensitive: A1 - Approval
No biomarker
Breast Cancer
letrozole
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
letrozole
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
anastrozole
Sensitive: A1 - Approval
No biomarker
Breast Cancer
anastrozole
Sensitive: A1 - Approval
ER negative
Breast Cancer
anastrozole
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
toremifene
Sensitive: A1 - Approval
HER-2 amplification
Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Breast Cancer
ixabepilone
Sensitive: A1 - Approval
BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
talazoparib
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A1 - Approval
No biomarker
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Breast Cancer
leuprorelin depot
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
trastuzumab + docetaxel
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval